Compile Data Set for Download or QSAR
Report error Found 164 Enz. Inhib. hit(s) with all data for entry = 2963
TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM387165(US9938276, G1)
Affinity DataIC50: 8.20nMAssay Description:The utility of the compounds in accordance with the present invention as orexin receptor OX1R and/or OX2R antagonists may be readily determined witho...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM387168(US9938276, H1)
Affinity DataIC50: 18.4nMAssay Description:The utility of the compounds in accordance with the present invention as orexin receptor OX1R and/or OX2R antagonists may be readily determined witho...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM387155(2-{(3aR, 7aR)-6-[(2- cyclobutylphenyl)carbonyl]oct...)
Affinity DataIC50: 31.1nMAssay Description:The utility of the compounds in accordance with the present invention as orexin receptor OX1R and/or OX2R antagonists may be readily determined witho...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM387139(2-((3aS, 7aS)-6-(2-(1H-pyrazol-1- yl)nicotinoyl)oc...)
Affinity DataIC50: 37nMAssay Description:The utility of the compounds in accordance with the present invention as orexin receptor OX1R and/or OX2R antagonists may be readily determined witho...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM387048(US9938276, A1)
Affinity DataIC50: 40.5nMAssay Description:The utility of the compounds in accordance with the present invention as orexin receptor OX1R and/or OX2R antagonists may be readily determined witho...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM387114((2-(2H-1,2,3-triazol-2-yl)phenyl)((3aR, 7aR)- 1-(i...)
Affinity DataIC50: 40.8nMAssay Description:The utility of the compounds in accordance with the present invention as orexin receptor OX1R and/or OX2R antagonists may be readily determined witho...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM387162(2-[(3aR, 7aR)-6-{[2-(2,2- difluorocyclopropyl)phen...)
Affinity DataIC50: 43.8nMAssay Description:The utility of the compounds in accordance with the present invention as orexin receptor OX1R and/or OX2R antagonists may be readily determined witho...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM387143(2-((3aR, 7aR)-6-(2-(2,2,2- trifluoroethyl)benzoyl)...)
Affinity DataIC50: 48.1nMAssay Description:The utility of the compounds in accordance with the present invention as orexin receptor OX1R and/or OX2R antagonists may be readily determined witho...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM387132(2-{3-[(3aR, 7aR)-6-{[2-(2H-1,2,3-triazol-2- yl)phe...)
Affinity DataIC50: 48.6nMAssay Description:The utility of the compounds in accordance with the present invention as orexin receptor OX1R and/or OX2R antagonists may be readily determined witho...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM387142(2-((3aR, 7aR)-6-(2- propylbenzoyl)octahydro-1H-pyr...)
Affinity DataIC50: 59.4nMAssay Description:The utility of the compounds in accordance with the present invention as orexin receptor OX1R and/or OX2R antagonists may be readily determined witho...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM387144(2-((3aR, 7aR)-6-(4-fluoro-2(2H-1,2,3- triazol-2-yl...)
Affinity DataIC50: 62.7nMAssay Description:The utility of the compounds in accordance with the present invention as orexin receptor OX1R and/or OX2R antagonists may be readily determined witho...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM387106((3aR, 7aR)-6-{[2-(2H-1,2,3-triazol-2- yl)phenyl]ca...)
Affinity DataIC50: 66.5nMAssay Description:The utility of the compounds in accordance with the present invention as orexin receptor OX1R and/or OX2R antagonists may be readily determined witho...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM387103(4-(dimethylamino)-2-[(3aR, 7aR)-6-{[2-(2H- 1,2,3-t...)
Affinity DataIC50: 69.8nMAssay Description:The utility of the compounds in accordance with the present invention as orexin receptor OX1R and/or OX2R antagonists may be readily determined witho...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM387158(2-{(3aR, 7aR)-6-[(3-phenylpyridin-2- yl)carbonyl]o...)
Affinity DataIC50: 76.9nMAssay Description:The utility of the compounds in accordance with the present invention as orexin receptor OX1R and/or OX2R antagonists may be readily determined witho...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM387137(2-((3aS, 7aS)-6-(2- (trifluoromethoxy)benzoyl)octa...)
Affinity DataIC50: 79.1nMAssay Description:The utility of the compounds in accordance with the present invention as orexin receptor OX1R and/or OX2R antagonists may be readily determined witho...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM387152(2-{(3aR, 7aR)-6-[(2- cyclopropylphenyl)carbonyl]oc...)
Affinity DataIC50: 81.6nMAssay Description:The utility of the compounds in accordance with the present invention as orexin receptor OX1R and/or OX2R antagonists may be readily determined witho...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM387101(2-(cis-6-(2-(2H-1,2,3-triazol-2- yl)benzoyl)ocathy...)
Affinity DataIC50: 84.8nMAssay Description:The utility of the compounds in accordance with the present invention as orexin receptor OX1R and/or OX2R antagonists may be readily determined witho...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM387145(2-((3aR, 7aR)-6-(2- phenylnicotinoyl)octahydro-1H-...)
Affinity DataIC50: 93.8nMAssay Description:The utility of the compounds in accordance with the present invention as orexin receptor OX1R and/or OX2R antagonists may be readily determined witho...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM387105(3-chloro-2-[(3aR, 7aR)-6-{[2-(2H-1,2,3-triazol- 2-...)
Affinity DataIC50: 95.5nMAssay Description:The utility of the compounds in accordance with the present invention as orexin receptor OX1R and/or OX2R antagonists may be readily determined witho...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM387156(2-{(3aR, 7aR)-6-[(2-pyrrolidin-1- ylphenyl)carbony...)
Affinity DataIC50: 98.9nMAssay Description:The utility of the compounds in accordance with the present invention as orexin receptor OX1R and/or OX2R antagonists may be readily determined witho...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM387163(2-{(3aR, 7aR)-6-[(2-pyrimidin-2- ylphenyl)carbonyl...)
Affinity DataIC50: 99.5nMAssay Description:The utility of the compounds in accordance with the present invention as orexin receptor OX1R and/or OX2R antagonists may be readily determined witho...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM387141(US9938276, E1)
Affinity DataIC50: 110nMAssay Description:The utility of the compounds in accordance with the present invention as orexin receptor OX1R and/or OX2R antagonists may be readily determined witho...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM387136(2-((3aS, 7aS)-6-(2-(2H-tetrazol-2- yl)benzoyl)octa...)
Affinity DataIC50: 110nMAssay Description:The utility of the compounds in accordance with the present invention as orexin receptor OX1R and/or OX2R antagonists may be readily determined witho...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM387140(2-((3aS, 7aS)-6-(3-(1H-pyrazol-1- yl)pyrazine-2-ca...)
Affinity DataIC50: 117nMAssay Description:The utility of the compounds in accordance with the present invention as orexin receptor OX1R and/or OX2R antagonists may be readily determined witho...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM387147(2-[(3aR, 7aR)-6-{[2-(2,2,2- trifluoroethoxy)pyridi...)
Affinity DataIC50: 122nMAssay Description:The utility of the compounds in accordance with the present invention as orexin receptor OX1R and/or OX2R antagonists may be readily determined witho...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM387133(2-{2-[(3aR, 7aR)-6-{[2-(2H-1,2,3-triazol-2- yl)phe...)
Affinity DataIC50: 125nMAssay Description:The utility of the compounds in accordance with the present invention as orexin receptor OX1R and/or OX2R antagonists may be readily determined witho...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM387104(6-chloro-N,N-dimethyl-2-[(3aR, 7aR)-6-{[2- (2H-1,2...)
Affinity DataIC50: 130nMAssay Description:The utility of the compounds in accordance with the present invention as orexin receptor OX1R and/or OX2R antagonists may be readily determined witho...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM387150(2-[(3aR, 7aR)-6-{[2-(2,2- difluoroethoxy)phenyl]ca...)
Affinity DataIC50: 139nMAssay Description:The utility of the compounds in accordance with the present invention as orexin receptor OX1R and/or OX2R antagonists may be readily determined witho...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM387135(US9938276, D1)
Affinity DataIC50: 147nMAssay Description:The utility of the compounds in accordance with the present invention as orexin receptor OX1R and/or OX2R antagonists may be readily determined witho...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM387088((2-(2H-1,2,3-triazol-2-yl)phenyl)((3aR, 7aR)-1- (4...)
Affinity DataIC50: 163nMAssay Description:The utility of the compounds in accordance with the present invention as orexin receptor OX1R and/or OX2R antagonists may be readily determined witho...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM387166(US9938276, G2)
Affinity DataIC50: 198nMAssay Description:The utility of the compounds in accordance with the present invention as orexin receptor OX1R and/or OX2R antagonists may be readily determined witho...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM387129(US9938276, C1)
Affinity DataIC50: 202nMAssay Description:The utility of the compounds in accordance with the present invention as orexin receptor OX1R and/or OX2R antagonists may be readily determined witho...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM387154(2-[(3aR, 7aR)-6-{[2-(1H-pyrazol-1- yl)phenyl]carbo...)
Affinity DataIC50: 256nMAssay Description:The utility of the compounds in accordance with the present invention as orexin receptor OX1R and/or OX2R antagonists may be readily determined witho...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM387149(2-[(3aR, 7aR)-6-{[2-(2,2,2- trifluoroethoxy)phenyl...)
Affinity DataIC50: 319nMAssay Description:The utility of the compounds in accordance with the present invention as orexin receptor OX1R and/or OX2R antagonists may be readily determined witho...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM387138(2-((3aS, 7aS)-6-(3-(pyridin-2- yl)pyrazine-2-carbo...)
Affinity DataIC50: 328nMAssay Description:The utility of the compounds in accordance with the present invention as orexin receptor OX1R and/or OX2R antagonists may be readily determined witho...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM387130((3aR, 7aR)-(2-(2H-1,2,3-triazol-2-yl)phenyl)-1- (4...)
Affinity DataIC50: 342nMAssay Description:The utility of the compounds in accordance with the present invention as orexin receptor OX1R and/or OX2R antagonists may be readily determined witho...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM387148(2-[(3aR, 7aR)-6-{[2-(2,2- difluoroethyl)phenyl]car...)
Affinity DataIC50: 512nMAssay Description:The utility of the compounds in accordance with the present invention as orexin receptor OX1R and/or OX2R antagonists may be readily determined witho...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM387164(US9938276, F1)
Affinity DataIC50: 562nMAssay Description:The utility of the compounds in accordance with the present invention as orexin receptor OX1R and/or OX2R antagonists may be readily determined witho...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM387121(((3aR, 7aR)-1-(1,7-naphthyridin-8- yl)hexahydro-1H...)
Affinity DataIC50: 750nMAssay Description:The utility of the compounds in accordance with the present invention as orexin receptor OX1R and/or OX2R antagonists may be readily determined witho...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM387109((3aR, 7aR)-(2-(2H-1,2,3-triazol-2- yl)phenyl)(1-(4...)
Affinity DataIC50: 766nMAssay Description:The utility of the compounds in accordance with the present invention as orexin receptor OX1R and/or OX2R antagonists may be readily determined witho...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM387107(US9938276, B1)
Affinity DataIC50: 902nMAssay Description:The utility of the compounds in accordance with the present invention as orexin receptor OX1R and/or OX2R antagonists may be readily determined witho...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM387089(2-((3aR, 7aR)-6-(2-(2H-1,2,3-triazol-2- yl)benzoyl...)
Affinity DataIC50: 943nMAssay Description:The utility of the compounds in accordance with the present invention as orexin receptor OX1R and/or OX2R antagonists may be readily determined witho...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM387126((3aR, 7aR)-1-(5,6-dimethylpyrazin-2-yl)-6- {[2-(2H...)
Affinity DataIC50: 948nMAssay Description:The utility of the compounds in accordance with the present invention as orexin receptor OX1R and/or OX2R antagonists may be readily determined witho...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM387153(2-{(3aR, 7aR)-6-[(2-cyclopropyl-6- methoxypyridin-...)
Affinity DataIC50: 980nMAssay Description:The utility of the compounds in accordance with the present invention as orexin receptor OX1R and/or OX2R antagonists may be readily determined witho...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM387124(4-[(3aR, 7aR)-6-{[2-(2H-1,2,3-triazol-2- yl)phenyl...)
Affinity DataIC50: 1.01E+3nMAssay Description:The utility of the compounds in accordance with the present invention as orexin receptor OX1R and/or OX2R antagonists may be readily determined witho...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM387108((3aR, 7aR)-(2-(2H-1,2,3-triazol-2- yl)phenyl)(1-(4...)
Affinity DataIC50: 1.01E+3nMAssay Description:The utility of the compounds in accordance with the present invention as orexin receptor OX1R and/or OX2R antagonists may be readily determined witho...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM387123(2-[(3aR, 7aR)-6-{[2-(2H-1,2,3-triazol-2- yl)phenyl...)
Affinity DataIC50: 1.05E+3nMAssay Description:The utility of the compounds in accordance with the present invention as orexin receptor OX1R and/or OX2R antagonists may be readily determined witho...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM387119((2-(2H-1,2,3-triazol-2-yl)phenyl)((3aR, 7aR)- 1-(i...)
Affinity DataIC50: 1.07E+3nMAssay Description:The utility of the compounds in accordance with the present invention as orexin receptor OX1R and/or OX2R antagonists may be readily determined witho...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM387146(2-{(3aR, 7aR)-6-[(2-ethoxypyridin-3- yl)carbonyl]o...)
Affinity DataIC50: 1.15E+3nMAssay Description:The utility of the compounds in accordance with the present invention as orexin receptor OX1R and/or OX2R antagonists may be readily determined witho...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM387117(methyl 2-((3aR, 7aS)-6-(2-(2H-1,2,3-triazol-2- yl)...)
Affinity DataIC50: 1.34E+3nMAssay Description:The utility of the compounds in accordance with the present invention as orexin receptor OX1R and/or OX2R antagonists may be readily determined witho...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

Displayed 1 to 50 (of 164 total ) | Next | Last >>
Jump to: